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& G2 (2)). Dice similarity coefficients (DSC) were used to compare G1 
and G2 spatial similarity. G1 and G2 defined structures were 
subsequently analysed for planned dose discrepancy. 
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Results: Differences in G1 and G2 delineation guidelines reported DSC 
values less than 0.5, indicating poor spatial correlation- SPCM 
(DSC=0.09±0.09, range of 0.02-0.22), MPCM (DSC=0.47±0.16, 
range:0.26 to 0.63), IPCM (DSC=0.34±0.12, range: 0.19 to 0.49), CP 
(DSC=0.33±0.12,range: 0.12 to 0.41), and OI (DSC=0.15±0.13, range: 0 
to 0.31). This difference in delineation led to dose differences for 
each structure (Dmean), shown inTable I, with some structures 
impacted by up to 13.9 %. Such variation is indicative of the variable 
proximity of the pharyngeal axis to areas of steep dose heterogeneity. 
In general, the range of per-structure dose differences across all 
patients was large, showing that indicated complication probability 
can be highly dependent upon which guideline is chosen for clinical 
use. 
Table 1. Dose difference of Dmean between structures delineated 
with G1 and G2 guidelines 
  
Conclusions: Whilst this study reported varying degrees of correlation 
between planned dosimetry and spatial incongruity, it highlights the 
potential of dosimetric variability with inconsistent delineation 
guidelines and the mandate to investigate with a larger patient cohort 
across multiple critical structures. When critical structures lie in close 
proximity to areas of steep dose heterogeneity, delineation disparity 
and subsequent dose discrepancy is of greater significance. Integrity 
of future DVO data demands a consensus on delineation guidelines to 
ensure recommendations are robust in clinical practice. 
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Purpose/Objective: To evaluate the effect of post-radiation adjuvant 
chemotherapy with oral tegafur-uracil in patients with high-risk 
nasopharygeal carcinoma (NPC) after combined chemoradiotherapy. 
Materials and Methods: Our definition of high-risk NPC included 
patients with 1) neck node > 6 cm; 2) supraclavicular node metastasis; 
3) skull base destruction/intracranial invasion plus multiple nodes 
metastasis; or 4) multiple neck nodes metastasis with one of nodal 
size > 4 cm. One hundred and sixty-three high-risk NPC patients 
finished full-course of concurrent chemoradiotherapy or neoadjuvant 
chemotherapy plus radiotherapy. Post-radiation adjuvant 
chemotherapy with oral tegafur-uracil (200 mg twice daily) for 12 
months was recommended to evaluate its impact on subsequent tumor 
relapse. One hundred and forty-one patients agreed to receive 
adjuvant oral tegafur-uracil. Twenty-two patients who refused 
adjuvant chemotherapy were served as a control. 
Results: After a median follow-up of 38 months, 32 of 141 (22.7%) 
patients with adjuvant tegafur-uracil developed tumor relapse later, 
whereas 59.1% (13/22) patients without adjuvant tegafur-uracil had 
tumor relapse. The progression-free survival rates were significantly 
higher in patients with adjuvant tegafur-uracil than those without 
adjuvant tegafur-uracil (P<0.0001). The adjuvant chemotherapy of 
tegafur-uracil was well-tolerated with no grade 3/4 toxicity. 
Conclusions: Post-radiation adjuvant chemotherapy with oral tegafur-
uracil for 12 months significantly reduced the relapse rate in high-risk 
NPC patients.  
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Purpose/Objective: A four-dimensional (4D) cone-beam CT (CBCT) is 
widely implemented in the precise radiation therapy of lung cancer 
treatment.In this study, we present a novel verification system for an 
image-guided radiation therapy (IGRT) by using in-treatment 4D CBCT 
acquired during Volumetric Modulated Arc Therapy (VMAT). 
Materials and Methods: A Stereotactic Body Radiation Therapy (SBRT) 
for lung cancer patient was performed by Elekta Synergy with a single-
arc VMAT. During the beam delivery, cone-beam projection images 
were sequentially acquired. A respiratory signal was reproduced by an 
image-based phase recognition technique computed with a normalized 
cross correlation between adjacent projections.Then, in-treatment 4D 
CBCT with four phase bins was reconstructed by in-house software and 
the CBCT sets were exported into the treatment planning system 
(TPS). After a registration of the CBCT center with the isocenter 
position in the corresponding treatment plan, the tumor location 
visualized in the CBCT for each phase was compared with that in the 
treatment plan. To see how this system works well, in particular, the 
center-of-mass (COM) of gross tumor volume (GTV) for maximum 
inhalation and exhalation for 10 patients was compared with those 
estimated by the planning CT. 
Results: The differences in maximum inhalation were 0.3 ± 1.3 mm, 
0.2 ± 1.7 mm, -0.7 ± 3.1 mm for the LR, AP, and CC directions, 
respectively,whereas the differences in maximum exhalation were 0.1 
± 1.3 mm, -0.4 ± 1.8 mm, -0.1 ± 1.9 mm for the LR,AP, and CC 
directions, respectively. 
Conclusions: In-treatment 4D CBCT is a direct method for 
quantitatively assessing the intrafractional location of a moving 
target. It was feasible to verify the tumor location during actual beam 
delivery with the system developed by using in-treatment 4D CBCT.  
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Purpose/Objective: Three–dimensional non-coplanar conformal 
radiotherapy (3-DNCCRT) has recently been considered promising for 
the treatment of stage I non-small cell lung cancer (NSCLC). Usually, 
it is performed in the form of SBRT using 10 – 20Gy fraction dose. 
However, this method is considered to be contraindicated for so-
called central tumors because of the toxicity of serial organs, such as 
bronchus, large vessels, etc. We have been treating these tumors with 
relatively small fraction dose (usually 3Gy) keeping BED10 at the 
similar level to that of SBRT. In this study, we analyzed our 10-year 
results. 
Materials and Methods: Eligibility criteria were as follows: maximum 
tumor diameter not greater than 5cm, PS between 0 and 2, and no 
limitation regarding age and pulmonary function. Radiotherapy was 
given with 6MV photon beam by fixed 10 non-coplanar conformal 
beams to a total dose of 75Gy in 25 fractionsin 5 weeks. Irradiation 
was aiming at the ITV with proper margins. No ENI was given. Between 
Jan. 2002 and Dec. 2010, 111 eligible cases were treated. Age ranged 
from 53 to 93 (median 78). The male/female ratio was 80/31. There 
were 64T1 tumors and 47 T2. Twenty-four tumors were sqcca, 71 
adenoca, and 16 others.There were 92 inoperable cases (83%), among 
them poor pulmonary function was in 66 (59%), and 19 operable cases, 
who refused operation. The average tumor size was 3.0 cm (range; 1.2 
to 5.0 cm). There were 102 PS 1 and 9 PS 2 cases. Among the entire 
cases, 46 cases were central tumors and the other 65 were peripheral 
tumors. Median follow-up period was 46 months.  
Results: Three- and 5-year local control rate (LC), overall survival 
rate (OS), cause-specific survival rate, and relapse-free survival rate 
for overall cases were, 85% and 85%, 67% and 50%, 79% and 65%, and 
56% and 41%, respectively. Three-year LC and OS for T1 and T2 cases 
were 87%, 66%, and 87%, 69%, respectively (n.s.). Three-year LC and 
OS for central and peripheral tumors were 85%, 70%, and 86%, 66%, 
respectively (n.s.). Three- and 5-year OS for operable and inoperable 
